Genisphere Licenses 3DNA Dendrimer Signal Amplification Technology to Chembio for Lateral Flow Rapid Test Applications

  Genisphere Licenses 3DNA Dendrimer Signal Amplification Technology to
  Chembio for Lateral Flow Rapid Test Applications

Business Wire

HATFIELD, Pa. -- July 29, 2013

Genisphere LLC has licensed its 3DNA® Signal Amplification technology to
Chembio Diagnostics, Inc., a leader in point-of-care ("POC") diagnostic tests
for infectious diseases. Chembio plans to use the signal enhancing technology
for its Dual Path Platform (“DPP®”) rapid diagnostic pipeline tests, with the
goal of achieving detection limits unique to rapid immunoassays thereby
broadening potential applications of its technology by combining it with the
Genisphere technology.

“Sensitivity, specificity and reproducibility are important features for all
diagnostic tests,” said Lawrence Siebert, Chembio's chief executive officer.
“We believe Genisphere’s technology can further enhance the performance of our
DPP® based assays leading to commercial success in this competitive

Genisphere’s 3DNA® Dendrimer technology has been used to improve the
performance of a variety of assay platforms for protein and nucleic acid
detection, including microarrays, ELISAs, bead-based flow cytometry, and most
recently, lateral flow assays. The 3DNA® Dendrimer technology provides up to
100-fold improvement in sensitivity without increasing the assay’s complexity.
This improved performance enables point-of-care analyses that have not
previously been possible with conventional systems.

The agreement between the two companies comes after a feasibility study in
which Genisphere demonstrated the 3DNA® Dendrimer can be adapted to Chembio's
Dual Path Platform. Such a close working relationship is a crucial part of
Genisphere’s approach.

“Genisphere’s business strategy is to partner with a few key successful
players in growing markets,” said Jim Kadushin, Genisphere’s chief operations
officer, “We believe Chembio is poised to continue its growth via the
combination of our technology with their assay and reagent development

Genisphere and Chembio will be presenting their respective products and
technologies at this year’s AACC meeting, to be held July 29 - Aug 2 in
Houston Texas.

About Genisphere

Genisphere LLC is a biotechnology company providing innovative tools for
targeted drug delivery, clinical diagnostics and life science research based
on the company’s 3DNA nanoparticle platform. Genisphere's unique,
IP-protected, 3DNA dendrimer technology has broad applicability to improve the
sensitivity in immunoassay and nucleic acid detection platforms, as well as to
deliver therapeutics in a highly specific manner. Genisphere has successfully
out-licensed several reagent kits to the research market, and provides
dendrimers customized to improve the limit of detection of high-sensitivity
lateral flow point-of-care tests, enabling their commercialization.
Genisphere's diagnostic partners have a competitive advantage due to 3DNA’s
ability to improve their test’s sensitivity, with minimal additional costs and
no alterations to end user protocols. For targeted therapeutics, Genisphere
provides the only customizable all-DNA drug delivery platform. Genisphere's
robust nanocarrier delivers small drug, RNAi and gene construct therapeutics
with greatly improved efficacy and reduced toxicity. The company is continuing
to seek partnerships with biotechnology and pharmaceutical companies that
could benefit from Genisphere's platform technology. For more information,
please visit

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit:


Jim Kadushin
Chempetitive Group
Ken Li
312-997-2436 x 109
Press spacebar to pause and continue. Press esc to stop.